Citation map · Study

SZodixStudyAcademic Library

Shelves Open access

Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated

Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework

3 references·15 citing·32 second hop

FromToDepth

this work references cited by second hop

References

2004Can the pharmaceutical industry reduce attrition rates?4,167 cited
2010How to improve R&D productivity: the pharmaceutical industry's grand challenge3,562 cited
2012Diagnosing the decline in pharmaceutical R&D efficiency1,978 cited

Cited by

2021A Decade of FDA-Approved Drugs (2010–2019): Trends and Future Directions323 cited
2016Changing R&D models in research-based pharmaceutical companies286 cited
2016When Quality Beats Quantity: Decision Theory, Drug Discovery, and the Reproducibility Crisis279 cited
2021Approval success rates of drug candidates based on target, action, modality, application, and their combinations113 cited
2016Opportunities and Challenges for Drug Development: Public–Private Partnerships, Adaptive Designs and Big Data103 cited
2021Trials and Terminations: Learning from Competitors’ R&D Failures98 cited
2014A decade of innovation in pharmaceutical R&D: the Chorus model81 cited
2021Achieving end-to-end success in the clinic: Pfizer’s learnings on R&D productivity66 cited
2015Human-based approaches to pharmacology and cardiology: an interdisciplinary and intersectorial workshop49 cited
2023Rival Signals and Project Selection: Insights from the Drug Development Process35 cited
2015How Many Molecules Does It Take to Tell a Story? Case Studies, Language, and an Epistemic View of Medicinal Chemistry

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work

33 cited

2021How does basic research improve innovation performance in the world’s major pharmaceutical firms?33 cited

2022From Financialisation to Innovation in UK Big Pharma24 cited

2016Assessing the Quality of Decision Making in the Development and Regulatory Review of Medicines: Identifying Biases and Best Practices11 cited

2023Many are called, few are chosen: the role of science in drug development decisions8 cited